title: Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients.
abstract: TT virus (TTV) is a recently described circular DNA virus of about 3.8 kb, which is related to the circoviridae viruses. It is commonly detected in healthy subjects and no association with any specific disease has been established. TTV was initially thought to be hepatotropic, but subsequent reports have shown that it is detectable in other tissues, including kidney, prostate, mammary gland, brain, bone marrow, and peripheral blood mononuclear cells. Plasma samples from cancer patients and healthy subjects were tested for the presence or absence of TTV by heminested polymerase chain reaction (PCR). We also developed a quantitative competitive PCR (QC-PCR) assay for TTV that permits accurate measurement of TTV DNA load. Using this assay, the TTV genome load in peripheral blood mononuclear cells (PBMCs) of healthy control subjects (n = 50) and patients with various types of cancer (n = 148), including breast cancer, non-Hodgkin's lymphoma, colon cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, and other cancers, was measured. TTV DNA was detected in 69 of 100 plasma samples (69%) of cancer patients tested and in 39 of 100 plasma samples (39%) randomly selected from 1000 plasma samples of blood donors (p < 0.05). TTV DNA was detectable in the PBMCs of 99% of the cancer patients and 86% of the controls. However, the median virus load was more than 100-fold higher in the cancer patients (3599 copies/100,000 cells) than among the controls (30 copies/100,000 cells; p < 0.0001). There was no significant difference in TTV load among the different cancer types. Using a cutoff value of >250 copies per 100,000 PBMCs, 93.2% of cancer patients were "positive" compared to only 4% of healthy control subjects. Almost all the cancer patients have TTV infection and their TTV genome load in PBMCs is significantly higher than that in control subjects. It remains to be elucidated whether such findings are specific to cancer patients or occur in all seriously ill subjects.
authors.affiliation: Department of Clinical Oncology, Institute of Molecular Oncology at the Sir Y. K. Pao Centre for Cancer, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories.
authors.forename: S
authors.initials: S
authors.lastname: Zhong
authors.forename: W
authors.initials: W
authors.lastname: Yeo
authors.forename: M W
authors.initials: MW
authors.lastname: Tang
authors.forename: X R
authors.initials: XR
authors.lastname: Lin
authors.forename: F
authors.initials: F
authors.lastname: Mo
authors.forename: W M
authors.initials: WM
authors.lastname: Ho
authors.forename: P
authors.initials: P
authors.lastname: Hui
authors.forename: P J
authors.initials: PJ
authors.lastname: Johnson
mesh_terms: D000328:Adult; D001483:Base Sequence; D016022:Case-Control Studies; D017931:DNA Primers; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D016679:Genome, Viral; D006801:Humans; D008297:Male; D009000:Monocytes / Q000821:virology*; D009369:Neoplasms / Q000097:blood / Q000821:virology*; D016133:Polymerase Chain Reaction; D022783:Torque teno virus / Q000235:genetics*; D019562:Viral Load
chemical_list: D017931:DNA Primers; D004279:DNA, Viral